Rifampicin in treating S aureus bacteraemia

Affiliations

¹ Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany. Electronic address: siegbert.rieg@uniklinik-freiburg.de.
² Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
³ IDIBAPS, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.

Comment

Siegbert Rieg et al. Lancet. 2018.

. 2018 Aug 18;392(10147):554-555.

doi: 10.1016/S0140-6736(18)31555-1. Epub 2018 Aug 16.

¹ Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany. Electronic address: siegbert.rieg@uniklinik-freiburg.de.
² Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
³ IDIBAPS, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.

No abstract available

Comment on

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG). Thwaites GE, et al. Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14. Lancet. 2018. PMID: 29249276 Free PMC article. Clinical Trial.